From September 14 to October 18, Servier will be present at the virtual edition of the ESMO (European Society for Medical Oncology) congress. ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information.
Servier, as a gold sponsor of the congress, will have the opportunity to reinforce its commitment to support the patients and their family with 2 digital platforms: Servier and WeHealth TM Digital Medicine.
The Servier virtual booth will provide medical education and information in colorectal, gastric and pancreatic cancers as well as haematological malignancies to healthcare professionals (HCPs). The Group will present its newly brochures (MyMood and My Dialogue), co-created with patients and stemming from the SHAPE program, whose objective is to develop, in collaboration with the DiCE coalition (patients, patient representatives, caregivers) and HCPs, tools to improve the quality of life of gastrointestinal cancer patients and support them throughout their cancer journey.
Servier is organizing two satellite symposia “Can current treatment strategies for metastatic colorectal cancer be further optimized?” and “Joining efforts beyond ﬁrst-line management in patients with metastatic pancreatic cancer”. For each symposium, there will be a pre-recorded scientific content on demand and a live Q&A session.
A poster from the SCOPE program will be presented. The SCOPE program, undertaken in 12 countries, aimed to assess ‘real world’ current clinical practice in patients with pretreated metastatic colorectal cancer. The objective was to gather insights to better understand medical and social factors influencing practice patterns and create value for HCPs.
WeHealth TM Digital Medicine, Servier’s e-health division, will present:
Servier employees in 50 countries are working each day to develop innovative therapeutic solutions in oncology.
Committed to fighting cancer, the Group intends to dedicate 50% of its global R&D budget to researching cancer treatments.
To boost its antibody capabilities and leverage its R&D pipeline, Servier acquired in June 2020 Symphogen, a leading antibody discovery company, including its pipeline of oncology and immuno-oncology programs as well as its antibody discovery and development platform. Symphogen is now Servier’s center of excellence for antibodies, strengthening the Group’s pipeline.